ホーム>>Signaling Pathways>> DNA Damage/DNA Repair>> Nucleoside Antimetabolite/Analogue>>Tipiracil

Tipiracil

カタログ番号GC37798

チピラシルは、チミジンホスホリラーゼ (TPase) 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Tipiracil 化学構造

Cas No.: 183204-74-2

サイズ 価格 在庫数 個数
5mg
$49.00
在庫あり
10mg
$70.00
在庫あり
50mg
$201.00
在庫あり
100mg
$335.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tipiracil is a thymidine phosphorylase (TPase) inhibitor. thymidine phosphorylase[1]

Tipiracil is an inhibitor of thymidine phosphorylase. Tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. The combination of Trifluridine and Tipiracil is a new oral treatment for metastatic colorectal cancer[2]. Tipiracil prevents degradation of FTD through a first-pass effect as a thymidine phosphorylase inhibitor[3].

[1]. Lee SJ, et al. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1327-35. [2]. Raedler LA. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):97-100. [3]. Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32(6):2319-26.

レビュー

Review for Tipiracil

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tipiracil

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.